OKYO Pharma Ltd ADR (OKYO) Peer Comparison
$1.35
$-0.05
(-3.57%)
As on 13-Nov-2026 16:27EST
Market cap
$75 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6
Div. Yield
0 %
Edit
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
75 | 3,154 | 1,862 | 1,853 | 1,227 |
Revenue ($ Mln) |
-- | 442 | 1,044 | 130 | 1 |
Net Profit ($ Mln) |
-8.95 | -198.39 | 488.78 | -46.09 | -59.95 |
Net Margin (%) |
-- | -44.91 | 46.83 | -35.42 | -9,759.23 |
RoE (%) |
-263.80 | -32.38 | 15.95 | -8.11 | -118.98 |
Price to Earnings |
-- | -- | 3.18 | -- | -- |
Price-To-Book |
5.96 | 5.60 | 0.49 | 3.23 | 31.91 |
Income Statement ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | -- | -- | 120.79 | -- |
|
Cost of Revenue
|
6.69 | -- | -- | 19.21 | -- |
|
Gross Profit
|
-6.69 | -- | -- | 101.58 | -- |
|
Operating Expenses
|
1.81 | -- | -- | 153.08 | -- |
|
Operating Profit (EBIT)
|
-8.50 | -- | -- | -51.50 | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-8.94 | -- | -- | -57.14 | -- |
|
Provision for Tax
|
0.01 | -- | -- | 0.62 | -- |
|
Profit after Tax (Net Income)
|
-8.95 | -- | -- | -57.76 | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
12.34 | -- | -- | 568.41 | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | -- | -- | 123.56 | -- |
|
Current Liabilities
|
8.64 | -- | -- | 81.11 | -- |
|
Total Liabilities
|
20.98 | -- | -- | 773.08 | -- |
Assets ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.01 | -- | -- | 575.59 | -- |
|
Current Assets
|
20.97 | -- | -- | 197.49 | -- |
|
Total Assets
|
20.98 | -- | -- | 773.08 | -- |
|
Total Debt*
|
-- | -- | -- | 127.33 | -- |
|
Net Current Assets
|
12.33 | -- | -- | 116.38 | -- |
Cashflow ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-5.94 | -- | -- | -43.83 | -- |
|
Cash Flow from Investing Activities
|
-6.01 | -- | -- | -1.02 | -- |
|
Cash from Financing Activities
|
25.02 | -- | -- | -15.33 | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-263.80 | -- | -- | -8.13 | -- |
|
ROE (%)
|
-263.80 | -- | -- | -9.91 | -- |
|
ROA (%)
|
-72.60 | -- | -- | -7.42 | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -- | -- | -47.82 | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | -- | 6.02 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-90.16 | -- | -- | 43.45 | -- |
|
EPS Growth (%)
|
-1.01 | -- | -- | 0.45 | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-6.73 | -- | -- | -30.40 | -- |
|
Price / Book Value
|
4.88 | -- | -- | 3.09 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-4.68 | -- | -- | -42.81 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -- | -- | 0.22 | -- |
|
Short term debt to equity ratio
|
-- | -- | -- | 0.02 | -- |
|
Current Ratio
|
2.43 | -- | -- | 2.43 | -- |
|
Quick Ratio
|
-- | -- | -- | 2.09 | -- |
|
Interest Coverage
|
-17.87 | -- | -- | -2.15 | -- |
Operating Efficiency Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | Mesoblast - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | -- | 47.74 | -- |
|
Asset Turnover
|
0.00 | -- | -- | 0.16 | -- |
|
Receivable days
|
-- | -- | -- | 109.66 | -- |
|
Inventory Days
|
-- | -- | -- | 478.70 | -- |
|
Payable days
|
410.43 | -- | -- | 509.43 | -- |
|
Cash Conversion Cycle
|
-- | -- | -- | 78.92 | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
